Stock comparison
IDEXX Laboratories
Medpace Holdings
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$42.11B
Sector
Healthcare
MEDP
Medpace Holdings
Market cap
$11.86B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | MEDP | Winner |
|---|---|---|---|
| Warren Buffett | 67B | 53C | IDXX |
| Benjamin Graham | 72B | 59C | IDXX |
| Philip Fisher | 67B | 62C | IDXX |
| Peter Lynch | 63C | 57C | IDXX |
| Joel Greenblatt | 75B | 71B | IDXX |
| Charlie Munger | 79B | 59C | IDXX |
| Terry Smith | 76B | 67B | IDXX |
Side-by-side metrics
| Metric | IDXX | MEDP |
|---|---|---|
| Market cap | $42.11B | $11.86B |
| P/E (TTM) | 39.0x | 25.7x |
| EV/EBIT | 31.6x | 21.2x |
| ROIC (TTM) | 40.66% | 56.06% |
| Gross margin | 62.05% | 29.07% |
| Net margin | 24.63% | 17.19% |
| Revenue CAGR 5y | 7.56% | 21.99% |
| EPS CAGR 5y | 10.79% | 32.59% |
| Debt / Equity | 0.7x | 0.2x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Market cap$42.11Bvs $11.86B+72%
- Gross margin62.05%vs 29.07%+53%
- Net margin24.63%vs 17.19%+30%
MEDP leads on
- EPS CAGR 5y32.59%vs 10.79%+67%
- Revenue CAGR 5y21.99%vs 7.56%+66%
- Debt / Equity0.2xvs 0.7x+65%
- P/E (TTM)25.7xvs 39.0x+34%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.